The lawsuit, filed by the Rosen Law Firm, alleges that the company engaged in deceptive practices by utilizing an undisclosed discount program. This scheme reportedly incentivized bulk orders that far exceeded actual procedure demand, artificially inflating U.S. handpiece sales and revenue figures. By the end of the class period, the complaint claims this practice created a surplus of over 10,000 units in field inventory.
In section Releases
Investors Face September 22 Deadline in PROCEPT BioRobotics Lawsuit
Investors who purchased PROCEPT BioRobotics common stock between February 28, 2024, and February 25, 2026, face a fast-approaching deadline to serve as lead plaintiff in a securities fraud class action. Those who sustained significant losses must move the court by September 22, 2026, to participate in the ongoing litigation.
According to the allegations, Procept’s public guidance for 2025 lacked a factual basis, leaving the company exposed to undisclosed financial and operational risks. When these details surfaced, the stock price decline allegedly caused substantial investor losses. While a class has not yet been certified, investors are encouraged to evaluate their legal options. Those wishing to participate in the case may contact attorney Phillip Kim at the Rosen Law Firm, which operates on a contingency fee basis for this matter.
Comments (0)
No comments yet. Be the first!